KineMed, Camino Partnership Collaborate to Create Portfolio of Clinical Drug Candidates

KineMed, Inc. KNMD and Camino Partnership, LLC today announced they are entering into a strategic partnership to locate and acquire control of a portfolio of new drug and targeted drug candidates. Once acquired, the collaboration will apply KineMed`s dynamic proteomics technology to carry out rapid proof-of-concept clinical studies for subsequent out-licensing to pharmaceutical companies. The initial therapeutic areas of focus will be oncology, neurodegenerative disorders, muscle wasting and fibrosis, particularly fibrosis of the liver. The collaboration intends to carry out de-risking proof-of-concept studies on up to six compounds over a three-year period. "By partnering with Camino, we are executing on our strategy to produce a pipeline of high-value drug candidates rapidly by leveraging the strength of our dynamic proteomics platform with Camino`s financial support and extensive global experience in developing drugs," said Patrick Doyle, president of KineMed. Harish Dave, managing partner of Camino, added, "Camino is focused on reducing the downside risk and creating value by accelerating the drug development process. We are delighted to collaborate with KineMed as they provide unique clinical insights into drug target engagement and processes of disease modification that can advantage Camino in accomplishing these goals